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he Development of the
on Willebrand Syndrome With
he Use of Continuous Flow
eft Ventricular Assist Devices
Cause-and-Effect Relationship*
eslie W. Miller, MD
ashington, DC
he use of ventricular assist devices (VADs) as a treatment for
nd-stage heart failure has increased substantially in the past 5
ears, due largely to the introduction and now proven superi-
rity of the second generation of VADs. These devices have a
otally new design that returns blood to the circulation by
onphasic, continuous flow (CF), as compared with the
rst-generation left ventricular assist device (LVAD), which
imicked the normal left ventricular function and provided
ulsatile blood flow (1). The results of recent trials have
onfirmed the very significant improvement in not only sur-
ival with this new design, but also significant increase in
unctional capacity and self-assessed quality of life (1–3).Major
dverse events have also decreased significantly in comparison
ith the first generation of pulsatile pumps, both with histor-
cal series using the same definition (1,4) and now with direct
omparison in clinical trials (1–3).
See page 1207
The 1 new adverse side effect associated with the CF pumps
s an increase in gastrointestinal (GI) bleeding (5,6). The fact
hat patients using CF pumps have more GI bleeding than was
een with pulsatile VADs is in part perhaps due to the new
equirement for the use of warfarin anticoagulation with the
F pumps. The most common cause of bleeding is typically
he development of arteriovenous malformations (AVMs),
ost often found in the proximal portion of the jejunum or
tomach (7,8). These lesions are often missed on routine upper
nd lower endoscopy and typically require newer “pill” endos-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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HF Solutions.opy to visualize, but have responded to endoscopic cauteriza-
ion in many cases (7,9).
The biology of the bleeding associated with CF VADs is
ultifactorial, but in this issue of the Journal, Uriel et al. (10)
ave provided a very important contribution to our under-
tanding of a potential cause-and-effect relationship between
he CF physiology and GI bleeding, and that is the develop-
ent of von Willebrand syndrome, as evidenced by near-total
epletion of the typical multimeric structure of the von
illebrand factor (vWF), which is a good biomarker of the
ntegrity of the vascular endothelium. The vWF levels were
art of a panel of factors that includes vonWillebrand antigen,
istocetin co-factor, and the von Willebrand multimers. Their
etrospective study demonstrated that all 18 patients who had
ocumented GI bleeding while on a CF pump had near-total
epletion of levels of vWF at the time of the bleed. They also
ound that the pre-operative levels of vWF were also almost
otally depleted in a similar number of CF VAD patients at the
ime of heart transplantation, although none of these patients
ad evidence of GI bleeding at the time. Importantly, the
ransfusion requirement after transplantation was 2-fold higher
n the CF patients in comparison with a cohort of patients who
nderwent heart transplantation after having been on a pulsa-
ile LVAD. There was a large SD in the levels of vWF
eported, and no clear cut point was identified in this small
ample size using any of the 3 components of the von
illebrand syndrome assay that could be used to predict risk of
leeding. Perhaps more convincing is the fact that the levels of
WF returned to normal very early after the VAD was
emoved at the time of heart transplantation and restoration of
ormal pulsatile blood flow. No other coagulation factors or
arkers of endothelial function were measured.
There are a number of potential explanations for the
evelopment of von Willebrand syndrome in these patients,
ut most attention has been focused on the observation of
imilar AVMs that develop typically in the distal colon in
lderly patients with calcific aortic stenosis (11,12). The
ommon denominator seems to be a very low pulse pressure
n both settings due to limited excursion of the stenotic
ortic valve with critical aortic stenosis, and thus very
arrow pulse pressure; similarly, the removal of nearly all
re-load in the left ventricle prevents the aortic valve
pening in most patients with a CF pump in place.
The question of why nonphasic blood flow, or very low
mplitude pulsatility, would lead to AVMs in such an
nusual location remains unclear. There is no vascular
natomic predisposition that would be common in all
atients experiencing a GI bleed with a CF pump in place,
or in patients with aortic stenosis. We have been condi-
ioned to believe that it is sheer stress from high turbulence
nd flow that generates atherosclerotic lesions. These data
uggest that the integrity of the vascular endothelium, as
videnced by the expression of border proteins such as vWF,
s in part dependent on the stretch and distension created by
ulsatile flow. It would seem counterintuitive, however, that
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October 5, 2010:1214–5 Development of the von Willebrand Syndromehe lack of pulsatile flow alone is a cause, as the measured
ean pressure is often elevated in patients with CF VADs,
nd the function of critical organs such as the kidney and
iver, as measured by biochemical markers, has been shown
o return to normal soon after CF VAD implant and remain
ormal for more than 6 months of follow-up (13).
One simplistic approach to address the question of the
ole of loss of pulsatility with CF pumps has been to slow
he pump speed, thus allowing more pre-load in the
entricle and measurable restoration of a normal 30 to 40
mHg pulse pressure and phasic flow. To date, this has not
een studied prospectively, and reports of its success in
ltering the frequency of clinical GI bleeding remain purely
necdotal, as warfarin anticoagulation is often stopped as
ell. Perhaps an equally important contribution of the Uriel
tudy (10) is that the levels of the components of the vWF
anel, especially vWF multimers, can be measured by many
aboratories on a prospective or routine basis. This could
otentially help to guide the level of anticoagulation used in
ach patient and hopefully avert GI bleeding from this cause.
One reasonable approach to test this hypothesis would be
o follow the levels of vWF after a period of time with
ltered pump speed to allow near-total return of pulsatile
lood pressure and observe whether bleeding reoccurs, or
ore importantly, whether the levels of vWF return to
ormal with pulsatile flow in the individual patient.
The single unfortunate aspect of the study (10) is that it was
etrospective, and thus levels were not measured in all patients
o determine whether patients with very low levels may not
leed, or more importantly, whether there is a threshold level
t which the risk of bleeding goes up substantially, which could
hus become a guide for adjustment of anticoagulation. The
hole issue of the long-term need for anticoagulation or what
evel of international normalized ratio is needed to prevent
ump thrombosis is unclear.. There are many anecdotal reports
f patients who experience significant bleeding and have had
ll anticoagulation stopped for months, with no apparent
lteration in VAD function. It also remains unclear whether
ntiplatelet agents alone, such as aspirin, are all that is needed
f the problem seems to be at the level of the endothelium. A
ignificant reduction in bleeding with CF pumps would be a
ritical advance, especially with the intended primary expan-
ion of VAD therapy into patients not considered candidates
or heart transplant due primarily to advanced age (65 years;
o-called “destination therapy”) (3). This population is less
apable of tolerating significant episodes of bleeding.
This study provides not only very important insight into the
iology and likely major contributor to the GI bleeding seen
ith CF VADs, but it provides the basis for prospective trials
esigned to monitor levels of vWF in these patients. The trial
esign could include a randomization of patients to various
reatments, such as adjustment of international normalized
atio levels based on the level of vWF, compared with a control
roup with more frequent monitoring without adjustment.
he study could be stopped early if it became clear that most
pisodes of clinical GI bleeding could be averted with this
K
yonitoring. Other aspects that need to be investigated include
hether aspirin alone is adequate protection from pump throm-
osis, as well as evaluation of whether various levels of pulsatile
ow created by VAD speed adjustment can alter the incidence of
I bleeding. Some of these studies are already underway at
olumbia University, where this study was performed, but
hese issues merit a multicenter study to be designed and
nitiated, ideally by the National Heart, Lung, and Blood
nstitute, with more patients to confirm the findings, because
his is not a problem unique to any one manufacturer.
Studies such as that by Uriel et al. (10) offer important
ontributions to identifying a potential cause of a common
nd serious adverse event, but also reveal important insight
nto the biology of nonpulsatile blood flow.
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